Pfizer Ltd has reported net sales growth of 10.1 per cent during the third quarter ended August 2010 to Rs. 225.61 crore from Rs. 204.84 crore in the corresponding period of last year. Its pharmaceutical sales increased by 14.2 per cent to Rs. 203.79 crore from Rs. 178.37 crore and income from animal health grew by 9.3 per cent to Rs. 28.88 crore from Rs. 26.43 crore. Its income from services – clinical development operations went up sharply by 48 per cent to Rs. 10.89 crore.

Its net profit, however, increased only by 3.2 per cent to Rs. 42.48 crore from Rs. 41.15 crore in the last period on account of significant growth in employees cost which went up almost by 54 per cent to Rs. 46.16 crore from Rs. 30.06 crore. Further, it provided Rs. 1.47 crore for VRS during the quarter. The earning per share for the quarter touched to Rs. 14.24 as against Rs. 13.79 in the last period.

For the first nine months ended August, 2010, Pfizer's net sales increased by 11.1 per cent to Rs. 640.55 crore from Rs. 576.66 crore in the similar period of last year. The sales from pharmaceutical segment increased by 13.1 per cent to Rs. 561.13 crore from Rs. 496.29 crore and that from animal health moved up by 7.6 per cent to Rs. 86.48 from Rs. 80.37 crore. Its EBDITA moved up by 4.9 per cent to Rs. 193.13 crore from Rs. 184.10 crore and its net profit increased by 7.3 per cent to Rs. 119.62 crore from Rs. 111.45 crore. EPS for the first half touched to Rs. 40.09 as compared to Rs. 37.35.

Pfizer Investments Netherlands B.V. and Pfizer Inc, announced an open offer to acquire up to 111.78 lakh equity shares on June 10, 2009. Of the total 211.13 lakh shares disclosed as Promoters and Promoter Group Shareholding, 88.10 lakh shares represent the shares tendered in the Open Offer. The current public holding worked out to 29 25 per cent.